Stock Events

Stock Events

Inventiva 

$4.33
91
-$0.20-4.42% 15:25 Today

Statistics

Day High
4.51
Day Low
4.25
52W High
7.15
52W Low
3.01
Volume
6,332,157
Avg. Volume
-
Mkt Cap
1.02B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25SepExpected
Q4 2023
Q1 2024
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Next
-2.07
-1.38
-0.69
0
Expected EPS
-0.40980082156
Actual EPS
N/A

Financials

-1,230.25%Profit Margin
Unprofitable
2015
2016
2017
2018
2019
2020
2.31MRevenue
-28.37MNet Income

Analyst Ratings

12.50Average Price Target
The highest estimate is 13.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IVA. It's not an investment recommendation.
NVIDIA
10
NVDA
TotalEnergies
9
TTE.PA
Microsoft
7
MSFT
Realty Income
7
O

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Lakefront Biotherapeutics NV
GLPG
Mkt Cap1.86B
Galapagos NV focuses on developing novel modes of action, including fibrosis treatments, competing in the same therapeutic areas as Inventiva.
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.18B
Madrigal Pharmaceuticals is involved in developing solutions for nonalcoholic steatohepatitis (NASH), a key area of focus for Inventiva.
Viking Therapeutics
VKTX
Mkt Cap4.35B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, making it a competitor.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences has a broad portfolio that includes treatments for liver diseases, such as NASH, competing with Inventiva's pipeline.
Agenus
AGEN
Mkt Cap126.18M
Agenus Inc. is focused on immuno-oncology but its interest in novel therapeutic approaches can indirectly compete with Inventiva's innovative treatments.
Abbvie
ABBV
Mkt Cap461.26B
AbbVie has a diverse biopharmaceutical portfolio that includes research in fibrosis, making it a competitor.
Pfizer
PFE
Mkt Cap138.61B
Pfizer has a broad research portfolio that includes fibrosis and other areas relevant to Inventiva's interests.
Novartis
NVS
Mkt Cap305.1B
Novartis AG conducts extensive research in areas including fibrosis and metabolic diseases, overlapping with Inventiva's therapeutic areas.

About

Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
Show more...
CEO
Mr. Andrew Obenshain
Employees
114
Country
France
ISIN
US46124U1079

Listings

XETRA
DE
6IV.XETRA
STU
DE
6IV.STU
STU
DE
6IVA.STU
MU
DE
6IV.MU

0 Comments

Share your thoughts

FAQ

What is Inventiva stock price today?▼
The current price of IVA is $4.33 USD — it has decreased by -4.42% in the past 24 hours. Watch Inventiva stock price performance more closely on the chart.
What is Inventiva stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Inventiva stocks are traded under the ticker IVA.
Is Inventiva stock price growing?▼
IVA stock has risen by +10.74% compared to the previous week, the month change is a +14.55% rise, over the last year Inventiva has showed a +28.11% increase.
What is Inventiva market cap?▼
Today Inventiva has the market capitalization of 1.02B
When is the next Inventiva earnings date?▼
Inventiva is going to release the next earnings report on September 25, 2026.
What were Inventiva earnings last quarter?▼
IVA earnings for the last quarter are -1.08 USD per share, whereas the estimation was -0.55 USD resulting in a -97.22% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Inventiva revenue for the last year?▼
Inventiva revenue for the last year amounts to 2.31M USD.
What is Inventiva net income for the last year?▼
IVA net income for the last year is -28.37M USD.
How many employees does Inventiva have?▼
As of July 10, 2026, the company has 114 employees.
In which sector is Inventiva located?▼
Inventiva operates in the Health & Wellness sector.
When did Inventiva complete a stock split?▼
Inventiva has not had any recent stock splits.
Where is Inventiva headquartered?▼
Inventiva is headquartered in Daix, France.